JG
CLDX icon

Jefferies Group’s Celldex Therapeutics CLDX Stock Holding History

Jefferies Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.59M Buy
127,700
+40,500
+46% +$1.24M 0.03% 425
2022
Q2 		$2.35M Buy
87,200
+7,000
+9% +$203K 0.02% 559
2022
Q1 		$2.73M Sell
80,200
-17,300
-18% -$553K 0.02% 582
2021
Q4 		$3.77M Buy
+97,500
New +$4.25M 0.02% 567
2020
Q4 		– Sell
-20,100
Closed -$298K – 1573
2020
Q3 		$298K Buy
+20,100
New +$235K ﹤0.01% 1096
2016
Q1 		– Sell
-980
Closed -$230K – 2246
2015
Q4 		$230K Buy
+980
New +$214K ﹤0.01% 1885
2014
Q2 		– Sell
-5,347
Closed -$1.42M – 2103
2014
Q1 		$1.42M Buy
+5,347
New +$2.05M 0.01% 752
2013
Q3 		– Sell
-2,400
Closed -$562K – 1955
2013
Q2 		$562K Buy
+2,400
New +$473K 0.01% 1014

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jefferies Group's CLDX Position: Q3 2022 in Review

Jefferies Group sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 59,098 shares — an estimated $1.81M sold.

Jefferies Group first reported a position in CLDX in Q2 2013 and held it in 10 quarters. The position peaked at $1.59M in Q2 2022. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Jefferies Group reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 59,098 Celldex Therapeutics shares in Q3 2022, an estimated $1.81M.
  • Jefferies Group first reported a position in Celldex Therapeutics in Q2 2013 and held it in 10 quarters.
  • Jefferies Group's Celldex Therapeutics position peaked at $1.59M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.